GalectoGLTO
Market Cap: $15M
About: Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
Employees: 13
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
200% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 3
0.27% more ownership
Funds ownership: 14.62% [Q1] → 14.89% (+0.27%) [Q2]
15% less funds holding
Funds holding: 26 [Q1] → 22 (-4) [Q2]
38% less capital invested
Capital invested by funds: $3.09M [Q1] → $1.91M (-$1.18M) [Q2]
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
Research analyst outlook
We haven’t received any recent analyst ratings for GLTO.